Semaglutide was effective in SELECT trial, unlike some lifestyle or pharmacologic interventions previously tested.10
CagriSema Phase 2 Proof-of-Concept (NCT04982575) Study Title: "Efficacy and Safety of Cagrilintide 2.4 mg in Combination With Semaglutide 2.4 mg for Weight Management" Status: Completed Phase: Phase 2 Enrollment: 92 participants Study Period: 2021-2022 Design: Randomized, double-blind, active-controlled Duration: 32 weeks Arms: CagriSema vs
Easier access contributes to greater adherence to the treatment plan
The sleep-deprived group lost more muscle mass instead
But some side effects, particularly for women, can be concerning, including the loss of muscle mass
These include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2, or history of pancreatitis